raziel therapeutics
The company develops RZL-012, a proprietary fat-dissolving injectable compound for focal fat reduction. Its clinical pipeline targets aesthetic applications such as submental fat and body contouring, as well as therapeutic treatments for Dercum’s Disease. The firm is currently conducting Phase 3 registration trials in China and has completed End of Phase 2 meetings with the FDA.
Visit websiteHod Hasharon, Israel
Healthtech
Biotechnology
Pharmaceuticals
Medical Aesthetics
Funding summary
- Total raised
- €18.9M
- Funding rounds
- 1
Investors in raziel therapeutics
Investors on record for raziel therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like raziel therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors